[Lab] SGN cagri — VendorInvestigate came back 97.4% against a claimed 97.0%
SGN cagri — VendorInvestigate came back 97.4% against a claimed 97.0%, and before anyone asks: same batch throughout, single submission, no cherry-picking between services. 97.4% and 97.0% — those are the numbers, and they are the ones I am willing to defend. Complementary mechanisms are the rationale for pairing:…
Why this compound is not simply another agonist, which is how it gets described everywhere else.
Amylin is co-secreted with insulin and signals satiety through its own receptor complexes. It is a different axis from the incretin system, not a parallel version of it. That is why the combination story is interesting: two mechanisms that address appetite differently, rather than more agonism at one receptor.
It is also why the dosing intuitions people bring from the semaglutide and tirzepatide boards do not transfer. Different receptors, different exposure-response, and no published schedule anybody here can reason from.
Went looking for independent results on this and found a handful across the whole site. That is the honest state of the evidence.
That result is preclinical. Worth flagging, since the thread has been reading it as human data.
Correcting myself upthread: I gave the 15-week figure and the paper reports 64 weeks.
Correction: that is the combination programme, not the monotherapy readout. Different arms, different numbers.